A study of 4 drugs for a rare kidney disease
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MIDD and have not yet received treatment for it (except for a small amount of steroids).
- Your overall health is fairly good (able to care for yourself and up and about more than half of the day).
- Your blood counts are stable: neutrophils at least 1.0, hemoglobin at least 7.0, and platelets at least 50.
- Your liver function is adequate (bilirubin and liver enzymes not too high).
- You do not have active multiple myeloma, another active cancer that has spread, or an uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
This trial tests a combination of three drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with rare kidney diseases caused by abnormal plasma cells. It aims to see if this treatment can help control the disease and protect kidney function.
Hear when a new Monoclonal Gammopathy of Renal Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.